Abstract
An estimated 17.6 per 100,000 new cases of childhood cancer are diagnosed each year in the United States. The major subtypes of childhood cancer include leukemia, central nervous system tumors, lymphoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, Germ cell tumors, and other rare tumors. Despite improvements in the diagnosis and treatment of these tumors over the last 30 years, subsets of children still have poor outcomes and many others have significant morbidity. Dysregulation of apoptotic pathways has been shown to contribute to tumor formation as well as resistance to therapy in both pediatric and adult malignancies. Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in diverse cancers and correlates with decreased patient survival. Here, we review the current literature on Survivin expression in pediatric cancer, its relationship to clinical outcome and potential therapeutic options to target this protein in pediatric cancer.
Keywords: Apoptosis, IAP, pediatric cancer, surviving, CNS tumor, caspase, Lymphoma, dysregulation, cytoplasm, Nucleus
Current Pediatric Reviews
Title: Inhibition of Apoptosis in Pediatric Cancer by Survivin
Volume: 7 Issue: 4
Author(s): Ayman Samkari and Rachel A. Altura
Affiliation:
Keywords: Apoptosis, IAP, pediatric cancer, surviving, CNS tumor, caspase, Lymphoma, dysregulation, cytoplasm, Nucleus
Abstract: An estimated 17.6 per 100,000 new cases of childhood cancer are diagnosed each year in the United States. The major subtypes of childhood cancer include leukemia, central nervous system tumors, lymphoma, neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, Germ cell tumors, and other rare tumors. Despite improvements in the diagnosis and treatment of these tumors over the last 30 years, subsets of children still have poor outcomes and many others have significant morbidity. Dysregulation of apoptotic pathways has been shown to contribute to tumor formation as well as resistance to therapy in both pediatric and adult malignancies. Survivin, the smallest member of the inhibitor of apoptosis protein (IAP) family, is highly expressed in diverse cancers and correlates with decreased patient survival. Here, we review the current literature on Survivin expression in pediatric cancer, its relationship to clinical outcome and potential therapeutic options to target this protein in pediatric cancer.
Export Options
About this article
Cite this article as:
Samkari Ayman and A. Altura Rachel, Inhibition of Apoptosis in Pediatric Cancer by Survivin, Current Pediatric Reviews 2011; 7 (4) . https://dx.doi.org/10.2174/157339611796892283
DOI https://dx.doi.org/10.2174/157339611796892283 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Subject Index to Volume 1
Current Pharmacogenomics Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Current Cancer Drug Targets Adolescents Attitudes Toward Vaccinations: A Systematic Review
Current Pediatric Reviews Cholestasis During Pregnancy: Aetiopathogenesis, Foetal-Maternal Repercussions and Pharmacological Treatments
Current Women`s Health Reviews Psychological Interventions for Parents of Children who have Cancer: A Meta-Analytic Review
Current Pediatric Reviews Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Chronic Granulomatous Disease in Childhood
Current Pediatric Reviews Interactions of Iron Oxide Nanoparticles with the Immune System: Challenges and Opportunities for their Use in Nano-oncology
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Flavonoids on Allergy
Current Pharmaceutical Design Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs
Current Gene Therapy The Effect of Sex and Gender on Diabetic Complications
Current Diabetes Reviews Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Clinicopathological Characteristics of Chinese Colorectal Cancer Patients under 30 Years of Age: Implication in Diagnosis and Therapy
Current Cancer Drug Targets What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy